USMLE Step 1 behavioral science & psychiatry questions

This adolescent is exhibiting normal exploration of beliefs, roles, and social groups, which is characteristic of Erikson's identity versus role confusion stage (ages 10-20 years). The developmental task of this stage is to integrate experiences, values, and social roles into a coherent sense of self; experimentation with different identities is expected and adaptive, not pathologic. Failure to resolve this stage results in role confusion, with a poorly defined sense of self and difficulty committing to goals or relationships. Reassurance to the parent and continued observation, rather than intervention, is appropriate here since there is no evidence of impaired functioning.

• A. This describes Erikson's intimacy versus isolation stage, which occurs in young adulthood, not adolescence.
• B. This describes a maladaptive outcome more consistent with inferiority, not the identity-formation process described here.
• C. This describes industry versus inferiority, the school-age stage (ages 6-12 years) focused on competence.
• E. This describes autonomy versus shame and doubt, the toddler stage, not adolescent identity formation.

This infant's withdrawal, poor eye contact, decreased responsiveness, and failure to thrive in the setting of prolonged maternal/caregiver deprivation are classic for anaclitic depression (hospitalism), first described by Spitz in institutionalized infants separated from consistent caregivers. Prolonged lack of a stable attachment figure during infancy can cause growth failure, developmental delay, and depressive-like withdrawal despite adequate nutrition being provided. The normal metabolic and infectious workup supports a psychosocial rather than organic etiology. Early intervention with consistent, nurturing caregiving can reverse many of these effects if started promptly.

• A. There is no history or examination finding (such as bruising or fractures) suggesting physical abuse in this vignette.
• C. Metabolic disorders would typically show abnormal laboratory findings or dysmorphic features, which are absent here.
• D. Autism spectrum disorder is a stable neurodevelopmental condition not caused by caregiver separation and would not be expected to resolve with improved caregiving.
• E. Congenital hypothyroidism presents with additional findings such as macroglossia, hypotonia, and an abnormal newborn screen, not isolated withdrawal from deprivation.

Decision-making capacity requires four elements: understanding the relevant information, appreciating the situation and its consequences, reasoning through the options in a logical, consistent manner, and expressing a clear choice. This patient has stated a choice but has shown inaccurate understanding (misdescribing surgery) and cannot demonstrate reasoning tied to the actual facts, so the physician must specifically probe his reasoning and understanding before concluding capacity is intact or absent. Capacity is decision-specific and task-based, assessed by the treating physician rather than automatically referred to psychiatry or ethics. Refusing a recommended treatment does not by itself indicate incapacity; the process of reasoning must be evaluated.

• A. Refusing a treatment that the physician believes is beneficial is not evidence of incapacity; capacity depends on the process of decision-making, not the outcome.
• B. Surrogate decision-makers are used only when a patient is determined to lack capacity, which has not yet been established.
• D. An ethics committee consultation is not the first step and is not used simply to override a patient's informed refusal.
• E. A psychiatric evaluation may be helpful in some cases but is not required to assess the four core elements of capacity and is not the immediate next step here.

Under the doctrine of implied consent for emergencies, a physician may proceed with treatment necessary to prevent death or serious harm when a patient is unable to give informed consent (due to unconsciousness or incapacity) and no surrogate is immediately available. This patient has hemorrhagic shock from a ruptured spleen, a life-threatening condition in which any delay to locate family, obtain a court order, or convene a committee could be fatal. The law presumes that a reasonable person would consent to life-saving treatment in this situation. Once the patient is stabilized or regains capacity, or a surrogate becomes available, ongoing decisions can then involve that input.

• B. Delaying time-critical, life-saving surgery to locate a surrogate risks the patient's death and is not required when implied consent applies.
• C. Ethics committee involvement is not required for emergency treatment under implied consent and would cause dangerous delay.
• D. Obtaining a court order is not feasible or necessary in a true life-threatening emergency.
• E. Waiting for the patient to regain consciousness is unsafe given his hemodynamic instability and risk of imminent death.

In the United States, minors are generally permitted to consent to their own care, without parental involvement, for sensitive services including sexually transmitted infection testing and treatment, contraception, and substance use treatment, reflecting public health interests in ensuring adolescents seek timely care. These exceptions exist because requiring parental consent for such services could discourage minors from seeking necessary medical care. The physician should proceed with confidential evaluation and treatment and maintain her privacy as permitted by law. This differs from most other medical decisions, where parental consent is otherwise required for minors.

• A. This situation does not require ethics consultation, as the legal standard for minor consent is already well established for this type of care.
• B. There is no indication of abuse or neglect here, so a child protective services report is not indicated.
• C. Parental consent is not required for STI testing and treatment under minor consent laws.
• E. Requiring a parent's presence would create a barrier to care for a condition the minor is legally allowed to consent to independently.

When a patient loses capacity, a previously designated health care power of attorney takes priority over default statutory surrogate hierarchies, including spouses, because the patient specifically chose that person to make decisions on their behalf. The power of attorney is expected to engage in substituted judgment, deciding as the patient would have decided based on known values and previously expressed wishes, even for situations not explicitly listed in the advance directive. An ethics committee or automatic default pathways are not appropriate first steps when a valid, specific surrogate has already been legally designated. This hierarchy exists to respect patient autonomy by honoring the patient's own choice of decision-maker.

• A. Ethics committee involvement is reserved for unresolved disputes or absence of a surrogate, not for routine decisions when a legal health care proxy exists.
• B. Lack of explicit mention of a specific treatment in the directive does not mean it should be automatically withheld; the designated surrogate should decide based on substituted judgment.
• C. Automatically initiating life-sustaining treatment without surrogate input disregards the designated decision-maker's role and the patient's autonomy.
• E. Default surrogate hierarchies (such as spouse) apply only when no health care power of attorney has been designated.

The Tarasoff duty to protect/warn requires a physician to breach confidentiality when a patient makes a specific, credible threat of serious harm against an identifiable victim, in order to protect that person from danger. This typically involves notifying the potential victim, law enforcement, or both, and may also include pursuing emergency psychiatric hospitalization of the patient if indicated. Confidentiality is an important ethical principle but is not absolute, and this exception is justified by the duty to prevent foreseeable serious harm to a specific third party. Simply documenting the threat or arranging future outpatient care does not fulfill this legal and ethical obligation.

• A. Waiting risks the safety of the identified victim and violates the duty to act proactively on a credible, specific threat.
• C. Confidentiality must be breached when there is a specific, credible threat to an identifiable third party under duty to warn/protect doctrine.
• D. Documentation alone is insufficient; active steps must be taken to protect the identified victim.
• E. This delays necessary protective action and does not address the immediate, specific threat described.

Physicians have an ethical and often legal obligation to report colleagues suspected of being impaired by substance use, especially when patient safety may be at risk, as in this case of an anesthesiologist diverting fentanyl while on duty. Reporting should be made to the appropriate body, such as a hospital physician health program, department chief, or state licensing board, which can arrange for evaluation, treatment, and monitoring while protecting patient safety. Relying on an impaired colleague's promise to self-correct is insufficient given the ongoing risk to patients from impaired judgment and motor function during surgery. The duty to report exists to protect both patients and the impaired physician, who can access confidential treatment programs designed for this purpose.

• A. Waiting for direct patient harm is unsafe and inconsistent with the ethical obligation to report impairment proactively.
• C. Further delay through repeated private confrontation prolongs the period of risk to patients from an impaired physician who is actively working.
• D. Self-referral without any formal reporting does not ensure accountability, monitoring, or verification that the physician is actually fit to practice.
• E. Relying solely on a private promise does not ensure patient safety or guarantee the colleague receives appropriate treatment and monitoring.

Malingering is the intentional production or exaggeration of symptoms for a recognizable external incentive, such as financial compensation, avoiding work, or obtaining disability payments. This patient has a clear secondary gain (a pending workplace injury claim) and welcomes further testing to support his claim, consistent with conscious, motivated symptom fabrication rather than genuine neurologic deficit. In contrast, conversion disorder involves unconscious production of neurologic symptoms, often following psychological stress, without a clear external incentive. Factitious disorder involves conscious symptom production but for an internal motivation (assuming the sick role), not external gain.

• B. Factitious disorder is driven by an internal need to assume the sick role, not external compensation.
• C. Illness anxiety disorder involves preoccupation with having a serious illness, not fabricated weakness for compensation.
• D. Conversion disorder involves unconscious symptom production, typically without an external financial motive.
• E. Somatic symptom disorder involves genuine distress about symptoms, not conscious fabrication for gain.

Specificity is the proportion of individuals without the disease (PCR-negative) who correctly test negative on the new test (true negatives divided by all disease-negative individuals). Here, true negatives = 270 and total PCR-negative = 300, giving specificity = 270/300 = 90%. Sensitivity, by contrast, would be calculated as true positives divided by all disease-positive individuals (180/200 = 90% in this case, coincidentally the same value). Confusing the denominator (using total positives instead of total negatives) is a common error.

• A. This resembles sensitivity-related miscalculation, not the correct specificity value.
• B. This value does not match true negatives (270) divided by total PCR-negative patients (300).
• D. This value does not correspond to true negatives over total negatives using the given numbers.
• E. This is the false negative proportion among PCR-positive patients, not specificity.

Sensitivity and specificity are intrinsic properties of a test and do not change with disease prevalence, but positive predictive value (PPV) and negative predictive value (NPV) are highly dependent on prevalence. As prevalence decreases, the proportion of false positives among all positive results increases, lowering PPV. Simultaneously, because true negatives become relatively more common, NPV rises toward 100%. This is why screening tests perform differently in a low-prevalence general population compared with a high-risk referral population.

• A. PPV and NPV both change substantially with prevalence even though sensitivity and specificity stay fixed.
• C. Sensitivity and specificity are fixed test characteristics and do not vary with prevalence.
• D. PPV decreases, not increases, as prevalence falls; NPV increases rather than decreases.
• E. Sensitivity and specificity remain constant regardless of prevalence changes.

This is a case-control study, because subjects are selected based on disease status (cases with mesothelioma and controls without) and exposure history is assessed retrospectively. In case-control studies, the odds ratio is the appropriate measure of association because the actual incidence or risk of disease in exposed versus unexposed populations cannot be directly calculated, since the proportion of cases and controls is set by the investigator rather than reflecting true population incidence. Relative risk, attributable risk, incidence rate, and absolute risk reduction all require a cohort design where incidence can be directly measured over time.

• A. Relative risk requires a cohort design that tracks incident disease in exposed versus unexposed groups over time.
• B. Incidence rate cannot be determined because the proportion of cases and controls is fixed by study design.
• C. Absolute risk reduction requires incidence data from a cohort or trial, not a case-control design.
• E. Attributable risk requires knowledge of incidence rates in exposed and unexposed cohorts.

A Type II error occurs when a study fails to reject the null hypothesis (concludes no difference) even though a true difference actually exists, often due to inadequate sample size or insufficient statistical power. The probability of a Type II error is denoted beta, and power equals 1 minus beta. In this scenario, the drug truly works, but the trial erroneously found no significant effect, which is the definition of a false negative, or Type II error. A Type I error, by contrast, is a false positive: concluding there is a difference when none truly exists.

• A. Information bias arises from measurement or classification errors, not from failure to detect a true effect.
• B. Confounding involves a third variable distorting the exposure-outcome relationship, not a failure to detect a true effect.
• C. A Type I error is a false positive, concluding a difference exists when it does not; here the opposite occurred.
• E. Selection bias arises from nonrandom selection of study participants, not from statistical power issues.

Confounding occurs when a third variable is associated with both the exposure and the outcome, distorting the apparent relationship between them. Here, smoking is associated with both coffee consumption (the exposure) and lung cancer (the outcome), and when the analysis is stratified by smoking status, the association between coffee and lung cancer disappears, confirming that smoking was confounding the original relationship. Stratification is a classic technique used during analysis to detect and control for confounding variables. Effect modification would instead show that the association differs in magnitude or direction between strata, not that it vanishes entirely.

• A. Reverse causality would mean lung cancer caused increased coffee consumption, which stratification by smoking does not address.
• B. Recall bias involves differential memory of exposure between cases and controls, not applicable in this prospective cohort.
• C. Selection bias concerns how participants were enrolled, not a third variable linked to exposure and outcome.
• E. Effect modification would show the coffee-cancer association varying in strength between smoking strata, not disappearing.

Lead-time bias occurs when screening detects a disease earlier in its natural history, which artificially lengthens the apparent interval between diagnosis and death (improving measured survival time) without actually changing the true time of death or the overall mortality rate. Because survival is measured from the time of diagnosis, earlier detection through screening mechanically increases survival duration even if the disease course and ultimate outcome are unaffected. This is why mortality rate, rather than survival rate, is the preferred outcome measure when evaluating the true effectiveness of a screening program.

• A. Length-time bias refers to screening preferentially detecting slower-growing, less aggressive tumors, not simply shifting the diagnosis time earlier.
• B. Overdiagnosis bias refers to detecting disease that would never have caused symptoms or death, which is a related but distinct phenomenon from lead-time bias.
• D. The healthy volunteer effect describes healthier individuals selectively participating in studies, which is not described here.
• E. Berkson bias is a hospital-based selection bias affecting case-control studies, not a screening survival artifact.

Acamprosate is thought to modulate NMDA (glutamatergic) and GABA-A receptor activity, helping to normalize the neuronal hyperexcitability that persists after chronic alcohol exposure and withdrawal. Because it is renally eliminated rather than hepatically metabolized, it is preferred over naltrexone in patients with significant liver disease. Naltrexone, in contrast, is a mu-opioid receptor antagonist that reduces the rewarding effects of alcohol but requires caution or avoidance in hepatic impairment. Disulfiram works by a completely different mechanism, causing acetaldehyde accumulation to produce aversive symptoms upon alcohol use.

• A. This describes naltrexone, which is relatively contraindicated in significant hepatic impairment.
• B. This describes varenicline, used for nicotine dependence, not alcohol use disorder.
• C. This is not the mechanism of any first-line alcohol use disorder maintenance medication.
• D. This describes disulfiram's mechanism, not the drug indicated here, and this patient's hepatitis makes it less ideal.

Caffeine withdrawal classically produces headache, fatigue, irritability, and difficulty concentrating within 12-24 hours of the last dose, peaking around 20-48 hours, consistent with this patient's timeline. Nicotine withdrawal typically presents with irritability, anxiety, increased appetite, and strong cravings, but headache is not a defining feature. Alcohol and benzodiazepine withdrawal are associated with autonomic hyperactivity (tachycardia, hypertension, tremor, diaphoresis) and can progress to seizures, none of which are present here. Opioid withdrawal produces piloerection, diarrhea, rhinorrhea, and myalgias rather than headache as the dominant symptom.

• B. Alcohol withdrawal presents with autonomic hyperactivity and tremor, which are absent here.
• C. Benzodiazepine withdrawal also causes autonomic instability and possible seizures, not seen in this stable patient.
• D. Nicotine withdrawal is characterized more by irritability, cravings, and increased appetite than by prominent headache.
• E. Opioid withdrawal presents with gastrointestinal symptoms, rhinorrhea, and myalgias, not isolated headache.

Major depressive disorder requires at least five of nine DSM-5 criteria (depressed mood, anhedonia, sleep disturbance, fatigue, appetite/weight change, concentration difficulty, psychomotor changes, feelings of worthlessness/guilt, suicidal ideation) present during the same 2-week period, with at least one being depressed mood or anhedonia, causing functional impairment. This patient meets five criteria (depressed mood, anhedonia, insomnia, fatigue, poor concentration, weight loss) over 3 weeks, satisfying the duration and symptom count requirement. A 1-month, 4-criterion standard does not match any DSM-5 category. A prior manic episode would suggest bipolar disorder, not MDD. The 2-year chronic, low-grade course describes persistent depressive disorder (dysthymia), not MDD, and an identifiable stressor is not required for MDD and would instead suggest an adjustment disorder if criteria for MDD were not met.

• A. A prior manic episode would indicate bipolar disorder, excluding a primary MDD diagnosis.
• B. This describes the duration criterion for persistent depressive disorder (dysthymia), not MDD.
• D. DSM-5 does not use a 1-month/four-criterion threshold for major depressive disorder.
• E. An identifiable stressor is not a required or defining criterion for major depressive disorder.

Persistent depressive disorder (dysthymia) requires a depressed mood present for most of the day, more days than not, for at least 2 years in adults (1 year in children and adolescents), without a symptom-free interval of more than 2 months during that period. This is distinct from major depressive disorder, which requires only 2 weeks of symptoms but with a higher symptom threshold. The patient's chronic, low-grade, 3-year course with no significant symptom-free periods fits the persistent depressive disorder duration criterion of at least 2 years. Shorter durations of 6 months or 1 year do not meet the DSM-5 threshold for this diagnosis in adults, and 5 years is longer than required.

• A. This is the minimum duration criterion for a major depressive episode, not persistent depressive disorder.
• B. This duration does not meet the DSM-5 threshold for persistent depressive disorder in adults (it is the pediatric criterion).
• D. This duration exceeds what is required; only 2 years is needed for diagnosis in adults.
• E. This duration does not meet the DSM-5 threshold for persistent depressive disorder in adults.

Postpartum ("maternal") blues occurs in up to 50-80% of women, begins within the first few days after delivery, peaks around day 4-5, and resolves spontaneously within 2 weeks without treatment; it does not impair the mother's ability to care for her infant. Postpartum depression has a later and more variable onset (typically within 4 weeks to several months postpartum), persists beyond 2 weeks, and requires treatment such as antidepressants or psychotherapy. Postpartum psychosis is a psychiatric emergency presenting with hallucinations, delusions, or disorganized behavior, typically within the first 2 weeks postpartum, and requires hospitalization due to risk of harm to the mother or infant. This patient's self-limited course and intact functioning are inconsistent with depression, psychosis, or a disorder requiring treatment.

• B. No significant psychosocial stressor-related impairment requiring treatment is described; this self-limited course is normal postpartum blues.
• C. There is no psychosis (hallucinations, delusions, disorganized behavior) present, and hospitalization is not indicated.
• D. The self-limited course under 2 weeks and intact functioning are inconsistent with postpartum depression, which persists longer and impairs functioning.
• E. This brief, self-limited course does not meet duration criteria for generalized anxiety disorder, which requires excessive worry for at least 6 months.

Generalized anxiety disorder is characterized by chronic, pervasive, difficult-to-control worry about multiple life domains lasting at least 6 months, accompanied by somatic symptoms such as muscle tension, restlessness, and sleep disturbance. Panic disorder, in contrast, is characterized by recurrent, discrete panic attacks: sudden, intense surges of fear peaking within minutes with symptoms such as palpitations, dyspnea, chest pain, and a sense of impending doom, often followed by persistent worry about having additional attacks. This patient's chronic, diffuse worry without discrete sudden attacks is the key distinguishing feature from panic disorder. Distress and impairment, muscle tension, and sleep disturbance can occur in both conditions and do not differentiate them, and both have minimum duration criteria (6 months for GAD, though panic disorder itself has no fixed duration requirement for the attacks).

• B. Her symptoms have actually been present for 10 months, exceeding the 6-month minimum, and duration alone is not what differentiates the two disorders.
• C. Significant distress and functional impairment can occur in both generalized anxiety disorder and panic disorder.
• D. Muscle tension and sleep disturbance are nonspecific somatic symptoms that can occur in both conditions.
• E. Ruling out substance use is a general requirement for diagnosing any anxiety disorder, not a distinguishing feature between these two conditions.

Social anxiety disorder is characterized by marked fear or anxiety about one or more social situations in which the person may be scrutinized by others, driven by fear of negative evaluation, embarrassment, or humiliation, as seen in this patient's avoidance of public speaking, eating in public, and social gatherings. Specific phobia involves fear of a particular object or situation (such as heights or animals) rather than fear of social scrutiny. Agoraphobia involves fear of situations such as open spaces, enclosed spaces, crowds, or being outside the home alone, driven by fear of being unable to escape or get help, not fear of embarrassment; this patient has no difficulty with buses, malls, or lines, which argues against agoraphobia. Panic disorder with agoraphobia requires a history of panic attacks, which is not described here. Avoidant personality disorder involves a pervasive, long-standing pattern of social inhibition and inadequacy beginning in early adulthood that is broader and more pervasive than situational social fears, and is a diagnosis of exclusion once social anxiety disorder is better explained.

• A. There is no mention of discrete panic attacks, which are required for this diagnosis.
• B. This describes social anxiety disorder's situational pattern rather than the pervasive, trait-like interpersonal dysfunction required for a personality disorder diagnosis.
• D. Specific phobia involves fear of a discrete object or situation rather than fear of social judgment across multiple social contexts.
• E. Agoraphobia is driven by fear of being unable to escape or get help in situations like crowds or open spaces, not by fear of social scrutiny, and this patient tolerates malls and buses.

Serotonin syndrome results from excess serotonergic activity at central 5-HT1A and 5-HT2A receptors, producing the triad of altered mental status, autonomic instability (hyperthermia, tachycardia, hypertension), and neuromuscular abnormalities (clonus, hyperreflexia, tremor, worse in the lower limbs). Combining an SSRI (fluoxetine) with a triptan (sumatriptan), both of which increase serotonergic tone, is a classic precipitant. Other serotonergic combinations include SSRIs with MAOIs, tramadol, or linezolid. Management includes stopping the offending agents, supportive care, and cyproheptadine (a 5-HT2A antagonist) for moderate-severe cases.

• A. Propranolol is a beta-blocker without significant serotonergic activity and does not precipitate serotonin syndrome.
• B. Amitriptyline does have serotonergic activity, but the absence of a recent dose change or new drug makes this combination a less likely acute trigger than the new triptan.
• C. Verapamil is a calcium channel blocker with no serotonergic activity.
• E. Topiramate acts on GABA and glutamate pathways, not serotonin, and is not a recognized trigger.

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that, particularly at higher doses, significantly increases synaptic norepinephrine by blocking its reuptake at the norepinephrine transporter. This increased noradrenergic tone can raise peripheral vascular resistance and cardiac output, producing dose-dependent hypertension. Blood pressure should be monitored periodically during venlafaxine therapy, especially with dose increases. This adverse effect is also seen with other SNRIs such as duloxetine, though typically to a lesser degree.

• A. Tyramine reactions occur with MAOIs, not SNRIs, and require dietary tyramine ingestion.
• C. Serotonin-induced coronary vasospasm is not a recognized mechanism of venlafaxine-associated hypertension.
• D. Venlafaxine has minimal anticholinergic activity compared with tricyclic antidepressants.
• E. Venlafaxine does not have clinically significant sodium channel blocking activity, unlike TCAs.

Tricyclic antidepressants block fast voltage-gated sodium channels in cardiac myocytes, slowing phase 0 depolarization and widening the QRS complex, which predisposes to ventricular arrhythmias and hypotension. Intravenous sodium bicarbonate increases extracellular sodium concentration and alkalinizes the serum, which enhances sodium channel binding kinetics and reduces drug-channel affinity, reversing cardiotoxicity. The target is a QRS duration under 100 ms and serum pH around 7.50-7.55. This is distinct from the anticholinergic and antihistaminergic toxicity (dry mucous membranes, dilated pupils, altered mental status) also seen in TCA overdose.

• B. Physostigmine, a cholinesterase inhibitor, can worsen cardiotoxicity by provoking bradyarrhythmias and is contraindicated in TCA overdose with cardiac conduction abnormalities.
• C. Magnesium sulfate is used for torsades de pointes or eclampsia, not first-line for TCA-induced QRS widening.
• D. Flumazenil reverses benzodiazepine toxicity and can precipitate seizures in mixed overdoses; it does not address sodium channel blockade.
• E. Calcium gluconate is used for calcium channel blocker overdose or hyperkalemia, not TCA-induced sodium channel blockade.

Monoamine oxidase inhibitors (MAOIs) block the breakdown of dietary tyramine, normally degraded by monoamine oxidase in the gut and liver. Excess tyramine acts as an indirect sympathomimetic, entering presynaptic sympathetic terminals and displacing stored norepinephrine into the synapse, causing a surge of norepinephrine release and severe vasoconstriction, producing a hypertensive crisis. Patients on MAOIs must avoid tyramine-rich foods such as aged cheeses, cured meats, and red wine. Treatment of the crisis involves rapid-acting antihypertensives such as IV phentolamine or nitroprusside.

• A. Tyramine is not a reuptake inhibitor; it is a substrate that is taken up and displaces stored norepinephrine.
• B. Tyramine does not directly bind or activate adrenergic receptors; its effect is indirect through norepinephrine release.
• D. The crisis results from excess release, not depletion, of norepinephrine stores.
• E. This mechanism does not involve central serotonin and is not the basis of the hypertensive crisis.

Chronic lithium use causes nephrogenic diabetes insipidus by accumulating in collecting duct principal cells and inhibiting adenylate cyclase downstream of the vasopressin (V2) receptor, reducing aquaporin-2 channel insertion into the apical membrane. This impairs the kidney's ability to concentrate urine despite normal or elevated antidiuretic hormone levels, explaining why urine osmolality fails to rise after desmopressin administration (unlike central diabetes insipidus, which responds to desmopressin). Management includes amiloride, which blocks lithium entry through epithelial sodium channels in the collecting duct, reducing nephrogenic DI symptoms while allowing continued lithium therapy.

• A. Lithium does not cause autoimmune destruction of the posterior pituitary; vasopressin secretion is intact.
• B. This is a renal concentrating defect, not an osmotic diuresis from increased GFR.
• C. Lithium toxicity does not cause glycosuria; this is unrelated to its nephrotoxic mechanism.
• E. Lithium toxicity does not cause destruction of hypothalamic osmoreceptors; the defect is renal, not central.

Valproic acid is a known human teratogen that increases the risk of neural tube defects (such as spina bifida) when taken during the first trimester, particularly during neural tube closure around weeks 3-4 of gestation. The proposed mechanism involves interference with folate metabolism and histone deacetylase inhibition affecting gene expression during neural tube closure. Valproate is also associated with dose-related hepatotoxicity and should be avoided in women of reproductive potential when possible; if used, high-dose folic acid supplementation and fetal ultrasound monitoring are recommended.

• A. Limb reduction defects are associated with thalidomide, not valproate.
• B. Valproate-associated anomalies primarily involve the neural tube, not an isolated craniofacial syndrome without neural tube involvement.
• C. Persistent pulmonary hypertension of the newborn is associated with late-trimester SSRI exposure, not valproate.
• E. Ebstein anomaly is classically associated with lithium exposure during pregnancy, not valproate.

Electroconvulsive therapy (ECT) is indicated for severe, treatment-refractory depression, depression with psychotic features, and cases requiring rapid response due to risk to life, such as food refusal or active suicidality, and it is considered safe during pregnancy at any trimester. ECT induces a generalized seizure through electrical stimulation, which is thought to work through widespread neurotransmitter release and neuroplastic changes, and has a rapid onset of action compared with pharmacotherapy. It avoids fetal exposure to high-dose psychotropic medications while rapidly resolving severe psychiatric symptoms. Obstetric monitoring is recommended during the procedure.

• A. Tricyclic antidepressants are not preferred for psychotic depression and would not provide the rapid response needed in this urgent case.
• B. MAOIs are not first-line and pose additional risks including hypertensive crisis; they are not indicated for this acute presentation.
• C. Further waiting with medication escalation delays treatment of an urgent, life-threatening presentation and risks worsening dehydration and fetal compromise.
• E. Clozapine is reserved for treatment-resistant schizophrenia and carries risks including agranulocytosis; it is not indicated here.

Buspirone is a 5-HT1A partial agonist used for generalized anxiety disorder. It lacks the sedative, dependence, and withdrawal potential of benzodiazepines because it does not act on GABA-A receptors, and its anxiolytic effect develops gradually over days to weeks rather than immediately. It has minimal abuse potential and does not cause significant sedation or cognitive impairment, making it suitable for patients who need to avoid these effects, such as commercial drivers.

• A. This describes SNRIs such as venlafaxine, not buspirone.
• B. This describes certain anticonvulsants and local anesthetics, not buspirone.
• C. This describes first-generation antihistamines, not an anxiolytic mechanism relevant here.
• D. This describes benzodiazepines, which cause dependence and are avoided here.

DSM-5-TR criteria for schizophrenia require continuous signs of disturbance for at least 6 months, which must include at least 1 month (or less if treated) of active-phase symptoms such as delusions, hallucinations, disorganized speech, grossly disorganized behavior, or negative symptoms, with at least two of these present and at least one being delusions, hallucinations, or disorganized speech. The remaining time can consist of prodromal or residual symptoms. This patient's 7-month history of delusions and hallucinations with functional decline meets this threshold.

• A. This duration describes schizophreniform disorder.
• B. This describes a requirement for schizoaffective disorder, not schizophrenia, and no mood episode is present here.
• C. This patient's presentation is not attributed to a medical condition, which would instead suggest psychosis due to another medical condition.
• E. This duration describes brief psychotic disorder.

Brief psychotic disorder involves the sudden onset of one or more psychotic symptoms (delusions, hallucinations, disorganized speech, or grossly disorganized/catatonic behavior) lasting at least 1 day but less than 1 month, with eventual full return to premorbid functioning. It is often triggered by severe psychosocial stressors, such as the sudden death of a loved one in this case. Schizophreniform disorder and schizophrenia require longer symptom durations (1-6 months and greater than 6 months, respectively), which this patient has not met.

• A. This diagnosis requires continuous illness for at least 6 months.
• B. This diagnosis requires non-bizarre delusions lasting at least 1 month without other prominent psychotic symptoms such as hallucinations.
• D. This diagnosis requires symptoms lasting 1 to 6 months, longer than this patient's expected course.
• E. This diagnosis requires a major mood episode overlapping with psychosis for most of the illness course, which is absent here.

Schizoaffective disorder requires an uninterrupted period of illness during which there is a major mood episode concurrent with active-phase psychotic symptoms, plus delusions or hallucinations for at least 2 weeks in the absence of a major mood episode at some point during the lifetime illness course. This patient had psychosis with a concurrent depressive episode for 2 months, followed by 12 months of psychosis alone, satisfying this criterion. In contrast, if mood symptoms were present for the majority of the illness, this would instead suggest a mood disorder with psychotic features.

• A. The timing relationship between onset of psychosis and resolution of the mood episode is not a diagnostic requirement.
• C. Schizoaffective disorder does not require two discrete depressive episodes; a single qualifying mood episode is sufficient.
• D. A mood episode present for the majority of the illness would argue against schizoaffective disorder and favor a mood disorder with psychotic features.
• E. There is no minimum duration of isolated psychosis required before a mood episode can occur; psychosis without mood symptoms for at least 2 weeks at any point satisfies the criterion.

The dopamine hypothesis of schizophrenia attributes positive symptoms, such as hallucinations and delusions, to excess dopaminergic activity in the mesolimbic pathway, which projects from the ventral tegmental area to the nucleus accumbens and limbic structures. Antipsychotics exert their therapeutic effect on positive symptoms primarily through D2 receptor blockade in this pathway. Decreased mesocortical dopaminergic activity, by contrast, is thought to contribute to negative and cognitive symptoms rather than positive symptoms.

• A. Decreased activity in this pathway is associated with negative and cognitive symptoms, not positive symptoms.
• C. This is not a recognized dopaminergic pathway implicated in antipsychotic pharmacology.
• D. This pathway regulates prolactin secretion, and D2 blockade here causes hyperprolactinemia rather than mediating positive symptoms.
• E. This pathway regulates motor control, and D2 blockade here causes extrapyramidal adverse effects rather than mediating positive symptoms.

Tardive dyskinesia arises after months to years of chronic dopamine receptor blockade, which leads to compensatory upregulation and supersensitivity of striatal dopamine receptors, producing involuntary, repetitive orofacial movements such as chewing, lip-smacking, and tongue protrusion. This contrasts with acute dystonia, which occurs within hours to days of starting or increasing a typical antipsychotic due to an acute imbalance favoring cholinergic activity after sudden D2 blockade, and which responds rapidly to anticholinergic agents like benztropine. Tardive dyskinesia may worsen, not improve, with anticholinergics or dose reduction withdrawal in the short term and is often irreversible.

• A. Tardive dyskinesia is caused by dopamine receptor supersensitivity, not an autoimmune process.
• B. This pathway mediates prolactin regulation and hyperprolactinemia, not movement disorders.
• D. This mechanism describes the acute dystonic reaction the patient had 9 years ago, not her current chronic movement disorder.
• E. This describes neuroleptic malignant syndrome, which presents with fever and rigidity, not isolated orofacial dyskinesia.

Neuroleptic malignant syndrome results from dopamine D2 receptor blockade in the hypothalamus and basal ganglia, leading to hyperthermia, lead-pipe rigidity, autonomic instability, and elevated creatine kinase from muscle breakdown. Dantrolene acts directly on skeletal muscle by blocking ryanodine receptor-mediated calcium release from the sarcoplasmic reticulum, reducing muscle contraction and rigidity. Bromocriptine, a dopamine agonist, is also used to treat neuroleptic malignant syndrome but acts centrally to restore dopaminergic tone rather than acting directly on muscle.

• B. This anticholinergic treats acute dystonia and parkinsonian adverse effects, not the muscle rigidity of neuroleptic malignant syndrome.
• C. This benzodiazepine can provide supportive sedation but does not act directly on skeletal muscle to reverse rigidity.
• D. This beta-blocker is not a standard treatment for neuroleptic malignant syndrome.
• E. This dopamine agonist is used for neuroleptic malignant syndrome but works centrally, not directly on skeletal muscle.

Clozapine carries a risk of agranulocytosis, defined as an absolute neutrophil count below 500/mm³, which can occur at any point during treatment but is most common in the first 6 months. Because of this risk, clozapine requires mandatory enrollment in a Risk Evaluation and Mitigation Strategy program with regular absolute neutrophil count monitoring, and the drug must be discontinued immediately if agranulocytosis develops. Clozapine is typically reserved for treatment-resistant schizophrenia because of this and other adverse effects, including myocarditis and seizures, but it is also notably effective, with minimal extrapyramidal symptoms, due to low D2 receptor affinity relative to other antipsychotics.

• A. This atypical antipsychotic is associated with sedation and metabolic adverse effects, not agranulocytosis requiring mandatory monitoring.
• B. This atypical antipsychotic is associated with hyperprolactinemia and extrapyramidal symptoms, not mandatory neutrophil monitoring for agranulocytosis.
• C. This typical antipsychotic is primarily associated with extrapyramidal symptoms and hyperprolactinemia, not agranulocytosis.
• E. This partial D2 agonist has a comparatively favorable metabolic profile and is not associated with agranulocytosis.

D2 receptor blockade in the tuberoinfundibular pathway removes tonic dopaminergic inhibition of lactotrophs, raising prolactin and causing galactorrhea or amenorrhea. D2 blockade in the nigrostriatal pathway disrupts the normal dopamine-acetylcholine balance in the striatum, producing extrapyramidal symptoms such as rigidity and tremor. The mesolimbic pathway is the site of therapeutic antipsychotic action against positive symptoms, and the mesocortical pathway's blockade is implicated in secondary negative symptoms, not these two findings. High-potency first-generation agents block D2 receptors strongly in all four pathways, producing this combined endocrine and motor picture.

• A. Mesocortical blockade causes secondary negative symptoms, not the findings described.
• B. Mesolimbic blockade underlies efficacy; nigrostriatal alone explains only the motor findings, not prolactin.
• C. These pathways account for antipsychotic efficacy and negative symptom worsening, not prolactin or EPS.
• E. Mesolimbic blockade underlies antipsychotic efficacy, not prolactin elevation.

Schizoid personality disorder is characterized by a pervasive pattern of detachment from social relationships and a restricted range of emotional expression, without the suspiciousness of paranoid personality disorder or the odd beliefs and perceptual distortions of schizotypal personality disorder. This man's preference for solitary work, lack of close friends, and emotional flatness without eccentric cognition fit this pattern. Avoidant personality disorder involves social withdrawal driven by fear of rejection, which is not described here. There is no evidence of psychosis or a prodromal/residual schizophrenic process.

• A. Paranoid personality disorder requires pervasive distrust and suspicion of others' motives, which this patient lacks.
• B. There is no history of psychotic symptoms required to diagnose schizophrenia, even in residual form.
• C. Avoidant personality disorder involves desire for relationships limited by fear of criticism or rejection, not indifference.
• E. Schizotypal personality disorder requires odd beliefs, magical thinking, or perceptual disturbances, which are absent here.

Splitting is an immature defense mechanism, classically seen in borderline personality disorder, in which a person views others (or themselves) as either all good or all bad, with inability to integrate positive and negative qualities into a coherent whole. This produces the characteristic oscillation between idealizing and devaluing the same individual, often triggered by a perceived slight such as a limit on behavior. Projection involves attributing one's own unacceptable feelings to another person, which is not occurring here. Reaction formation would involve expressing the opposite of an unacceptable impulse, and denial involves refusal to accept a painful reality, neither of which fits this alternating pattern.

• A. Denial involves refusing to acknowledge a distressing reality, not oscillating evaluations of another person.
• B. Projection involves attributing one's own unacceptable thoughts or feelings to another person, not alternating views of one person.
• D. Identification involves adopting characteristics of another person, which is unrelated to this alternating pattern.
• E. Reaction formation replaces an unacceptable feeling with its opposite, not alternating extremes toward the same person.

DSM-5 criteria for antisocial personality disorder require that the individual be at least 18 years old and have evidence of conduct disorder with onset before age 15 years, in addition to a pervasive pattern of disregard for the rights of others since age 15. This patient's childhood history of truancy, fighting, animal cruelty, and vandalism satisfies the conduct disorder requirement. Conduct disorder is essentially the childhood/adolescent precursor, and its presence before age 15 is a mandatory diagnostic link rather than simply one option among several childhood diagnoses. Oppositional defiant disorder is a distinct, generally less severe diagnosis and is not required for antisocial personality disorder.

• B. An arrest is not a formal diagnostic requirement; the criterion is conduct disorder before age 15, not a legal record.
• C. Antisocial personality disorder can coexist with mood or substance use disorders; their absence is not required.
• D. Oppositional defiant disorder is a separate diagnosis and is not a prerequisite for antisocial personality disorder.
• E. Chronic unemployment can be a feature of the irresponsibility criterion but is not itself a required diagnostic element.

Factitious disorder imposed on another (previously called Munchausen syndrome by proxy) involves a caregiver falsifying or inducing illness in a dependent, typically a child, to assume a sick role by proxy and gain attention or sympathy from medical staff, without an external incentive such as financial gain. The evidence of tampering with the IV line to induce symptoms, combined with the mother's eagerness for medical attention, is classic for this diagnosis. Somatic symptom disorder and illness anxiety disorder involve a person's genuine preoccupation with their own symptoms or health, not induction of illness in another person. Malingering involves conscious symptom fabrication for an external, tangible incentive such as disability payments or avoiding work, which is not evident here.

• A. Malingering requires a clear external incentive like financial gain, which is not present in this caregiving scenario.
• C. "Munchausen syndrome" as a diagnosis applies to self-induced illness in oneself, and the diagnosis here belongs to the mother, not the child.
• D. Illness anxiety disorder involves preoccupation with having an illness oneself despite few or no symptoms, not inducing disease in a child.
• E. Somatic symptom disorder refers to the patient's own excessive concern about their own physical symptoms, not fabricating illness in another person.

Reaction formation is an immature defense mechanism in which an unacceptable unconscious impulse or feeling is converted into its direct opposite in conscious behavior, often expressed with excessive or exaggerated intensity. This man's unconscious same-sex attraction is being unconsciously transformed into overt, vehement opposition to homosexuality. Projection would involve attributing his own attraction to others rather than expressing the opposite behavior himself. Displacement redirects an emotion toward a safer, substitute target rather than converting it into its opposite, and sublimation channels an unacceptable impulse into a socially acceptable, constructive activity rather than its negation.

• A. Projection would involve him accusing other people of harboring same-sex attraction, not adopting the opposite stance himself.
• C. Sublimation channels an unacceptable impulse into a constructive, socially valued outlet, not into direct opposition to it.
• D. Displacement redirects an emotional response onto a less threatening target, rather than converting the feeling into its opposite.
• E. Rationalization uses logical-sounding justifications to explain away behavior, rather than unconsciously converting an impulse into its opposite.

In anorexia nervosa, severe negative energy balance and low leptin levels reduce hypothalamic gonadotropin-releasing hormone (GnRH) pulsatility, leading to functional hypothalamic hypogonadism. This causes low or low-normal LH and FSH, which in turn produce low estradiol and secondary amenorrhea, essentially reverting to a prepubertal hormonal pattern. Ovarian failure would show high, not low-normal, gonadotropins due to loss of negative feedback. Hyperprolactinemia is not typically a feature of anorexia nervosa and would be expected to show elevated prolactin, which is not given here.

• A. Primary ovarian failure causes elevated LH and FSH due to loss of negative feedback, not the low-normal levels seen here.
• B. No prolactin elevation is reported, and hyperprolactinemia is not a typical feature of anorexia nervosa.
• D. Cortisol elevation can occur in starvation but is not the primary mechanism of amenorrhea in anorexia nervosa.
• E. Thyrotropin-releasing hormone elevation implies primary hypothyroidism, which is not the mechanism of amenorrhea described and not indicated by the labs.

Repeated self-induced vomiting in bulimia nervosa causes direct loss of hydrochloric acid from the stomach, producing a hypochloremic metabolic alkalosis. The accompanying volume depletion activates the renin-angiotensin-aldosterone system, and aldosterone promotes renal sodium reabsorption in exchange for potassium and hydrogen ion secretion in the distal nephron, worsening both hypokalemia and the alkalosis in a self-perpetuating cycle. This combination of low chloride, low potassium, and elevated bicarbonate is the classic laboratory pattern of vomiting-induced metabolic alkalosis. Starvation ketosis would produce an anion gap metabolic acidosis, not alkalosis, and is not supported by the given electrolyte pattern.

• A. Volume depletion contributes to bicarbonate retention, but it is a secondary consequence, not the primary mechanism described, and ignores the dominant role of hydrogen ion loss itself.
• B. Hypokalemia can impair ammonium excretion in the kidney, but this is not the primary driver of the alkalosis described in this clinical pattern.
• D. Ketone body accumulation causes an anion gap metabolic acidosis, which is inconsistent with this patient's elevated bicarbonate.
• E. There is no history given of bicarbonate ingestion; the clinical history points specifically to self-induced vomiting as the cause.